The Biz Bucks Blog provides former Biz Bucks students and other busy professionals with a summary and commentary of seminal articles from the opinion pages of the Wall Street Journal. You can be notified of a new posting by subscribing to the blog (enter email in box on right) or by following on Twitter: @BizBucksGuy.

The Next Progressive Passion: Ending Drug Innovation September 30, 2015 2:00 PM | Tagged as Drug, Sovaldi

WSJ Sept 23, 2015, page A12:  “The Assault on Drug Innovation” (editorial)

When The Biz Bucks Guy was in his MBA program twenty years ago, Dr. Alan Shapiro ask us an interesting question, “How many pharmaceutical drugs were developed in the former Soviet Union from 1917 (its beginning) to 1989 (it breakup)?” The answer is a nice round number…zero!  Command economies don’t innovate. Whether you call it communism, socialism, progressivism, totalitarianism, the economy therein is run by the government. We can thank our market economy in the US for most of the innovations in anything, including pharmaceutical drugs.

But wait! Why should these Big Pharma companies make so much money? Isn’t it immoral that they charge so much to help people? Shouldn’t the poor have access to not only healthcare but the chemistry industry’s output? These are the questions of the left. You are now hearing from the left that ObamaCare did not go far enough. The left wants HillaryCare 2.0 which will bend the prices of drugs downward into the affordability range for all to partake whenever necessary.

The problem is it is largely governmental regulations that make drug innovation so expensive. Firms must recoup their R&D budget. They don’t hit homeruns every attempt.

When the market works, good things happen. Consider this account:

One of the big gripes from the left is the price for Sovaldi, the Hepatitis C drug. Originally, it cost over $80,000 to cure an individual. However, the treatment time was much less than other options which made the expense of the drug cost effective. Soon, much to the consternation of the left, other Big Pharma companies began to R&D in that area. The market was working. Now there are three competitors. This has caused price of this Hep C therapy to plunge. This is how our system works. Without a free market, Hep C victims would be in for a tough ride for a long time.

The left (specifically Bernie Sanders and Hillary Clinton) have made statements about price controls in the Big Pharma industry. The elitists think they know the true cost for a new drug. Where do they plan to divine that number from?  

Kiss drug innovation good-bye if either one becomes president.

[Although opinion is included, The Biz Bucks Blog is primarily written to former students of Biz Bucks training courses to encourage their daily reading of the three opinion pages of the WSJ. This refreshes principles of Biz Bucks courses and improves business acumen on topics not discussed in Biz Bucks training.]

Posted By The Biz Bucks Guy
Posted in Price Controls | 0 Replies

Subscribe to Our Blog

To receive email updates when a new post is made, please enter your email address in the box below and click Subscribe.


Use these key words to search past blogs:



1994 97% Alesina Recession Alinsky Allesina austerity Baloney BAT Binz bird kills Bogle Border Adjustment Tax Brulle Bryce capitalism carbon Carbon Dioxide CBO CFTC chains China Churchill Climate Climate Change Clinton Comparative Advantage Crichton Cronyism Cummins Curry Darwin Death panel demographics population economics Denier derivatives Dodd-Frank Drug dynamic Dynamic Scoring education electric car Energy Energy Policy Enron Debt Entitlements Eugenics Fat Fry Flat Earthers fracking free markets free trade Free Trade E-Verify Free Trade Zoellick Freedom Heritage Foundation Friedman gas lines Gas Prices glaciers Global Warming Global Warming Sustainability global warming subsidies IMF Globalization Trade God Google Gore Gramm Green Blob Grifo Groupthink Growth Hannity Hayek Hostess Hybrid Immigration Imports index funds Indexing Intellectual Denial investing investment IPCC JFK Joint Tax Kennedy Kerry Keynes Keynesian Keynesian Tax Cuts King Barak Bird Kills Koch Koonin Laffer Lamar Smith Lomborg macroeconomics macroeconomics;static; dynamic MACT Makiel markets Marxist medical care minimum wage Mitchell Model T Moore Morgenthau Navarro Neumark NOAA NY Times Obamacare ObamaCare Rove Health Insurance O'Reilly participation rate Patrick Moore peer review Peer Review EPA Piketty Pipelines plywood Presidential authority Price Controls Pruitt Racial divide Rare Earth Reagan Recession REE Renewable Portfolio Standards Renewables Ricardo Ridley robotics RPS Ryan Schlaff Science science integrity scoring Settled Science Shaffer shortages socialism socialized medicine Solar Panels Solvaldi Sovaldi static steel STEM Stephens Steyer stimulus subsidies subsidy sugar Supreme Creator tax policy tax reform Taylor territorial taxes corporate taxes Tesla Trade train wreck Trump unemployment wages Wind wind power women Zuckerman